Truvada should remain first choice for HIV prevention, experts say

(Harvard Pilgrim Health Care Institute) In October 2019, the FDA approved a second medication for use as HIV preexposure prophylaxis, also known as PrEP, sparking controversy about which drug should be prescribed. Gilead Sciences, which manufactures both approved drugs, has argued that the new drug is safer and more effective than the old drug. But these claims are overstated, say a team of clinical and public health experts.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news